Agenus (AGEN) : Tuesdays money flow indicated an uptick to downtick ratio was at 4.95. The total value of inflow transactions on upticks was $0.1 million, whereas, the total value of outflow trades on downticks was $0.02 million. The total money flow was $0.08 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $0.05 million. The total value of the trades done on upticks was $0.05 million. Agenus (AGEN) was trading with a -1.06% change over previous days close. It fell $0.05 during the day and reached $4.66. The stock was -2.71% compared to the previous weeks close.
The company Insiders own 7.6% of Agenus shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 7.7% . Institutional Investors own 41.72% of Agenus shares. During last six month period, the net percent change held by insiders has seen a change of 32.06%. In an insider trading activity, The Securities and Exchange Commission has divulged in a Form 4 filing that the CEO of Agenus Inc, Armen Garo H had purchased shares worth of $318,000 in a transaction dated on May 6, 2016. A total of 100,000 shares were purchased at a price of $3.18 per share. The information is based on open market trades at the market prices.Option exercises are not covered.
Shares of Agenus Inc. rose by 12.56% in the last five trading days and 21% for the last 4 weeks. Agenus Inc. is up 11.52% in the last 3-month period. Year-to-Date the stock performance stands at 6.61%.
Agenus (NASDAQ:AGEN): stock turned positive on Tuesday. Though the stock opened at $4.76, the bulls momentum made the stock top out at $4.92 level for the day. The stock recorded a low of $4.65 and closed the trading day at $4.84, in the green by 2.76%. The total traded volume for the day was 1,125,135. The stock had closed at $4.71 in the previous days trading.
Agenus Inc. (Agenus) is an immunotherapy company. The Company is engaged in discovering and developing treatments for patients with cancer and other diseases. Its approaches are driven by three platform technologies: Its antibody platform, including Retrocyte Display technology, which is designed to produce human monoclonal antibodies focused on advancing checkpoint modulators (CPMs); its heat shock protein (HSP)-based vaccines, and its saponin-based vaccine adjuvants, QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company has a portfolio of programs in pre-clinical and clinical stages, including a series of CPMs in investigational new drug (IND)-enabling studies, Prophage Series vaccine, a Phase III ready HSP-based autologous vaccine for glioblastoma multiforme (GBM), which is a form of brain cancer, and a number of QS-21 Stimulon-containing vaccine candidates in late stage development by its partner, GlaxoSmithKline (GSK).